444 related articles for article (PubMed ID: 30677052)
1. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.
Liu T; Yang H; Fan W; Tu J; Li TWH; Wang J; Shen H; Yang J; Xiong T; Steggerda J; Liu Z; Noureddin M; Maldonado SS; Annamalai A; Seki E; Mato JM; Lu SC
Gastroenterology; 2018 Aug; 155(2):557-571.e14. PubMed ID: 29733835
[TBL] [Abstract][Full Text] [Related]
4. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
[TBL] [Abstract][Full Text] [Related]
5. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
[No Abstract] [Full Text] [Related]
6. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte nuclear factor 6 inhibits the growth and metastasis of cholangiocarcinoma cells by regulating miR-122.
Zhu H; Mi Y; Jiang X; Zhou X; Li R; Wei Z; Jiang H; Lu J; Sun X
J Cancer Res Clin Oncol; 2016 May; 142(5):969-80. PubMed ID: 26825606
[TBL] [Abstract][Full Text] [Related]
8. FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.
Lv B; Ma L; Tang W; Huang P; Yang B; Wang L; Chen S; Gao Q; Zhang S; Xia J
Cell Physiol Biochem; 2018; 48(1):158-172. PubMed ID: 30001540
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
10. Forced overexpression of FBP1 inhibits proliferation and metastasis in cholangiocarcinoma cells via Wnt/β-catenin pathway.
Zhao W; Yang S; Chen J; Zhao J; Dong J
Life Sci; 2018 Oct; 210():224-234. PubMed ID: 30193944
[TBL] [Abstract][Full Text] [Related]
11. The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway.
Attia YM; Tawfiq RA; Ali AA; Elmazar MM
Sci Rep; 2017 Oct; 7(1):12502. PubMed ID: 28970500
[TBL] [Abstract][Full Text] [Related]
12. TGF-β signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: A study on human primary cell cultures.
Lustri AM; Di Matteo S; Fraveto A; Costantini D; Cantafora A; Napoletano C; Bragazzi MC; Giuliante F; De Rose AM; Berloco PB; Grazi GL; Carpino G; Alvaro D
PLoS One; 2017; 12(9):e0183932. PubMed ID: 28873435
[TBL] [Abstract][Full Text] [Related]
13. Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells.
Di Matteo S; Nevi L; Overi D; Landolina N; Faccioli J; Giulitti F; Napoletano C; Oddi A; Marziani AM; Costantini D; De Rose AM; Melandro F; Bragazzi MC; Grazi GL; Berloco PB; Giuliante F; Donato G; Moretta L; Carpino G; Cardinale V; Gaudio E; Alvaro D
Sci Rep; 2021 Jan; 11(1):2557. PubMed ID: 33510179
[TBL] [Abstract][Full Text] [Related]
14. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms.
Guo C; LaCerte C; Edwards JE; Brouwer KR; Brouwer KLR
J Pharmacol Exp Ther; 2018 May; 365(2):413-421. PubMed ID: 29487110
[TBL] [Abstract][Full Text] [Related]
16. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
Mancarella S; Serino G; Dituri F; Cigliano A; Ribback S; Wang J; Chen X; Calvisi DF; Giannelli G
Cell Death Differ; 2020 Aug; 27(8):2330-2343. PubMed ID: 32042099
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
[TBL] [Abstract][Full Text] [Related]
18. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Bordoni M; Roselli R; Di Giorgio C; Baldoni M; Ricci P; Monti MC; Morretta E; Zampella A; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158733. PubMed ID: 32371093
[TBL] [Abstract][Full Text] [Related]
19. Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma.
Zhang H; Li Z; Chu B; Zhang F; Zhang Y; Ke F; Chen Y; Xu Y; Liu S; Zhao S; Liang H; Weng M; Wu X; Li M; Wu W; Quan Z; Liu Y; Zhang Y; Gong W
Tumour Biol; 2016 Jun; 37(6):8305-15. PubMed ID: 26729195
[TBL] [Abstract][Full Text] [Related]
20. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
Fiorucci S; Di Giorgio C; Distrutti E
Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
